MEI Pharma, Inc. (MEIP) - Utang jangka dawa marang modal

The financial price action for MEI Pharma, Inc. (MEIP) illustrates the debt-to-equity dynamics, which currently stand at 0.00. MEI Pharma, Inc. (MEIP) focuses on developing blood tumor therapies through alliances with biopharma partners. The operating model relies on full outsourcing of synthesis and testing to third-party organizations without maintaining in-house facilities. However, the business is currently seeking ways to survive after losing ground to more successful market solutions.

This ratio is calculated as the proportion of liabilities with a maturity of more than one year to total equity. The metric determines financial stability and the extent of the company's dependence on borrowed funds over the long term. For MEI Pharma, Inc. (MEIP), a low debt load is critical given the extensive outsourcing of clinical trials through a network of CROs. This ensures operational autonomy and protection against credit risks. Current long-term debt-to-equity price action confirms the reliability of this strategy.